Skip to main content

Table 5 Risks of death and hospitalisations: subgroup analysis in patients 65 years or older

From: Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study

Event

Aspart vs lispro

Glulisine vs lispro

Glulisine vs aspart

Total Mortality

1.10 [0.84, 1.44]

0.61 [0.37, 1.02]

0.56 [0.36, 0.87]

CHD

1.02 [0.83, 1.26]

1.09 [0.78, 1.52]

1.06 [0.81, 1.40]

Fatal CHD

1.18 [0.74, 1.89]

0.85 [0.38, 1.90]

0.72 [0.37, 1.40]

CVD

0.95 [0.78, 1.14]

0.98 [0.72, 1.33]

1.04 [0.80, 1.34]

Fatal CVD

1.15 [0.75, 1.78]

0.76 [0.36, 1.61]

0.66 [0.35, 1.23]

Stroke

0.86 [0.56, 1.33]

0.28 [0.11, 0.71]*

0.32 [0.14, 0.76]*

Heart Failure

0.97 [0.75, 1.25]

0.74 [0.47, 1.18]

0.77 [0.51, 1.15]

Kidney Failure

0.78 [0.58, 1.06]

0.68 [0.38, 1.22]

0.87 [0.52, 1.46]

Hypoglycaemia

2.37 [1.07, 5.25]*

3.24 [1.12, 9.42]*

1.37 [0.65, 2.88]

Hyperglycaemia

4.67 [1.49, 14.65]*

0.39 [0.09, 1.64]

0.39 [0.09, 1.64]

  1. Weighted Cox proportional hazards analysis. Estimated hazard ratios with 95% confidence intervals. * p-value <0.05